Delivery Order SPE2DB20D3101-SPE2DB25FRRU6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Tasigna 150 mg capsules (28-count) valued at $6,007.90 under a firm fixed-price contract type. The award, issued on August 7, 2025, with an ultimate completion date of August 28, 2025, represents a non-competitive delivery against AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be supplied to the place of performance in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Tasigna 150 mg capsules (28-count units) with a ceiling value of $6,007.90. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 29, 2025, and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $6,007.90 to AmerisourceBergen Drug Corp for Tasigna 150 mg capsules (28-count units) on July 23, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Tasigna is a specialized oncology medication used in the treatment of chronic myeloid leukemia, reflecting the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tasigna 200 mg capsules (28-count units) under a firm fixed-price contract valued at $6,007.90. The award, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive delivery against AmerisourceBergen's larger Indefinite Delivery Contract vehicle. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $6,007.90 to AmerisourceBergen Drug Corp for Tasigna 150 mg capsules (28-count packaging) with a firm fixed price structure. This non-set-aside contract was awarded on July 30, 2025, with an ultimate completion date of August 20, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction under the company's...
- The Defense Logistics Agency awarded a $6,007.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tasigna 200 mg capsules (28-count units) on September 15, 2025, with an ultimate completion date of October 6, 2025. The contract is unclassified with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a critical vendor in the federal medical procurement supply...
- The Defense Logistics Agency awarded a delivery order valued at $6,007.90 to AmerisourceBergen Drug Corp for the supply of Tasigna 150 mg capsules (28-count units) under a firm fixed price contract. This non-competitive delivery order, issued on August 8, 2025, with an ultimate completion date of August 29, 2025, will be performed at the awardee's facility in Conshohocken, Pennsylvania. Tasigna is a specialized oncology medication used in the treatment of certain types of leukemia, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Tasigna 150 mg capsules (28-count units) with a ceiling value of $6,007.90. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 24, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract represents a non-set-aside procurement under the company's existing...
- The Defense Logistics Agency awarded a $6,007.90 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Tasigna 150 mg capsules (28-count packages). This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The contract will be completed by September 2, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $6,007.90 delivery order to AmerisourceBergen Drug Corp for Tasigna 200 mg capsules (28-count) on July 23, 2025, with an ultimate completion date of August 13, 2025. This competitive, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement. The pharmaceutical product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRU6Delivery Order
The Defense Logistics Agency has awarded a delivery order valued at $6,007.90 to AmerisourceBergen Drug Corp for the supply of Tasigna 200 mg capsules (28-count packaging). This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 25, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania will serve as the place of performance for this pharmaceutical supply delivery. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. As the prime contractor under this IDC, AmerisourceBergen provides a broad range of pharmaceutical products and medical supplies to support military and federal healthcare systems, including the Defense Health Agency and U.S. Coast Guard. Tasigna is a specialty medication used in the treatment of chronic myeloid leukemia, demonstrating the company's role in supplying critical therapeutic agents to federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 8/4/25 |